For the clinical application of gene therapy against kidney fibrosis targeting TGF-β, we need to introduce genetic material into mesangial cells in patients with glomerulosclerosis, or interstitial fibroblasts in patients with interstitial fibrosis. Here, TGFB1 is linked to glomerulosclerosis.